Form 4: Belite Bio CSO Executes Planned ADS Sale

Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares of Belite Bio, Inc. pursuant to a pre-established Rule 10b5-1 trading plan.

Summary

• Nathan L. Mata, Chief Scientific Officer of Belite Bio, Inc., sold a total of 1,000 American depositary shares (ADS) on April 20, 2026.
• The transactions were executed in multiple tranches at weighted average prices ranging from $162.7552 to $168.35 per share.
• Following these transactions, the reporting person retains beneficial ownership of 12,666 American depositary shares.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on December 10, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted under a pre-planned 10b5-1 arrangement, which is a standard practice for executive financial management.

Positives

• The sale was executed under a pre-arranged Rule 10b5-1 trading plan, which is designed to avoid concerns regarding insider trading by establishing sales in advance.

Negatives

• The sale represents a reduction in the equity stake held by a key member of the executive leadership team.

Risks

• Insider selling can sometimes be perceived negatively by the market, potentially impacting short-term investor sentiment.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing, as it is a standard disclosure of insider transaction activity.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is common in the biotechnology sector, particularly among executives looking to diversify personal holdings after significant share price appreciation.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to manage equity holdings while maintaining regulatory compliance.
• The volume of shares sold is relatively small compared to the total outstanding shares, which is typical for executive liquidity events.

Stakeholder Impact

• Minimal impact expected on shareholders as the transaction was pre-planned and represents a small portion of the executive's holdings.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Belite Bio, BLTE, Insider Trading, Form 4, Chief Scientific Officer, Rule 10b5-1